Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia

Abstract

SUMMARYA cross-sectional study with internal comparison groups was conducted to describe sociodemographic characteristics, as well as verify the association between the type of antiretroviral treatment used and hyperglycemia and hyperlipidemia, with special attention to the use of HIV protease inhibitors. The data was obtained through an interview questionnaire, as well as blood and urine samples that were collected for the laboratory exams. A total of 418 patients were interviewed. 46 of these, however, met the exclusion criteria. The sample was therefore composed by 372 HIV positive patients, attended at the laboratory of the Correia Picanço State Hospital for the collection of blood, to estimate the HIV viral load and/or TCD4 cell counts from August to November 2000. The association between the variables was tested using the chi-square test and the p-value. A multiple logistic regression analysis was carried out to adjust for potential confounding factors. A greater frequency of patients with high glucose levels was observed among those making use of antiretroviral therapy without protease inhibitors, but the number of patients limited the comparisons. An association was verified between the total serum cholesterol level and the use of HIV protease inhibitors (p = 0.047) even after controlling for age. An association was also observed between the triglyceride levels and the use of HIV protease inhibitors, which remained after adjustment for age, sex and creatinine levels (p < 0.001). The levels of glucose and TSH, the presence of proteinuria and the practice of physical activity were not associated either with the levels of cholesterol or with the levels of tryglicerides thus they were not confounders of the associations described.

Associação entre o uso de antirretrovirais no tratamento para HIV e alterações físicas e metabólicas

“…Inúmeros eventos estão relacionados a alterações psíquicas, endócrino-metabólicas e físicas que levam ao desenvolvimento de enfermidades como hipertensão, diabetes mellitus (PAPI et al, 2014), dislipidemias (GUEVARA et al, 2008), disfunções hormonais (PONTE et al, 2009), alterações hematológicas como anemia, leucopenia e trombocitopenia (KIBARU et al, 2015), nefropatias (ARAÚJO et al, 2007) e ainda manifestações psicossociais (REMOR, 2002).…”

“…Para o século XXI, vários estudos demonstram que o uso de HAART pode induzir a um processo de instalação de Síndrome Metabólica (SM) (ACOSTA et al, 2013;ALMEIDA et al, 2009;ARAÚJO et al, 2007;GUEVARA et al, 2008;SIGNORINI, et al, 2010;VALENTE et al, 2005;VASIMON, et al, 2011). A SM é um conjunto de fatores de risco, relacionados entre si, com patogênese multifatorial e que predispõe ao desenvolvimento de hipertensão, diabetes mellitus e dislipidemias (GUEVARA et al, 2008).…”

Experiência da adesão ao tratamento entre mulheres com Vírus da Imunodeficiência Humana/ Síndrome da Imunodeficiência Adquirida

“…Nevertheless, researches show another picture, the body marks, and the image that has to be taken care of, when the side effects produced by the inhibitors come up, such as: lipodystrophy, cardiovascular disease risks, dislipidemy, hyperglycemia, factors that have to be considered when living with HIV/AIDS (2)(3)(4) .…”

Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil

“…The advent of combined antiretroviral therapy (cART) increased survival, and resulted in the emergence of complications nonexistent or not perceived, until then, and thought to be drug-related adverse effects. These complications included body fat redistribution, increased fat mass, and changes in circulating lipids and glucose metabolism, all contributing to increased cardiovascular risk (CVR) (5)(6)(7)(8)(9)(10)(11)(12).…”